E X T R A Dement Geriatr Cogn Disord Extra 20166283294 DOI 101159000447239 Published online July 15 2016 2016 The Authors Published S Karger AG Basel wwwkargercomdee This article licensed Creative Commons AttributionNonCommercialNoDerivatives 40 Interna tional License CC BYNCND httpwwwkargercomServicesOpenAccessLicense Usage distribu tion commercial purposes distribution modified material requires written permission Original Research Article Increased Cerebrospinal Fluid Levels Ubiquitin CarboxylTerminal Hydrolase L1 Patients Alzheimers Disease Annika Öhrfelt Per Johansson b d Anders Wallin Ulf Andreasson Henrik Zetterberg e Kaj Blennow Johan Svensson c d Clinical Neurochemistry Laboratory Department Psychiatry Neurochemistry Institute Neuroscience Physiology Sahlgrenska University Hospital Mölndal Sahlgrenska Academy University Gothenburg Mölndal b Department Neuropsychiatry Skaraborg Hospital Falköping c Department Endocrinology Skaraborg Hospital Skövde d Institute Medicine Sahlgrenska Academy University Gothenburg Gothenburg Sweden e UCL Institute Neurology London UK Key Words Alzheimers disease Biomarkers Cerebrospinal fluid DJ1 Neuronspecific enolase Ubiquitin carboxylterminal hydrolase L1 Tau phosphorylated threonine 231 Abstract Background Dysfunctions ubiquitin proteasome UPS including highly abundant neuronal enzyme ubiquitin carboxylterminal hydrolase L1 UCHL1 autoph agyrelated changes lysosomal degradation implicated neurodegenerative disorders including Alzheimers disease AD Method This study evaluated cerebrospinal fluid CSF levels UCHL1 protein deglycase DJ1 neuronspecific enolase NSE tau phosphorylated threonine 231 Ptau 231 independent patient control cohorts Cohort 1 included CSF samples subjects having AD biomarker profile n 10 control biomarker profile n 31 cohort 2 monocenter clinical study including patients AD n 32 mild cognitive impairment n 13 dementias n 15 cognitively healthy controls n 20 Results UCHL1 Ptau 231 elevated AD patients compared controls cohorts CSF levels DJ1 NSE unchanged AD group decreased group dementia compared controls clinical study Conclusion Our main findings support UPS pathway impaired AD UCHL1 serve additional CSF biomarker AD 2016 The Authors Published S Karger AG Basel Annika Öhrfelt Clinical Neurochemistry Laboratory Department Psychiatry Neurochemistry Institute Neuroscience Physiology Sahlgrenska University Hospital Mölndal Sahlgrenska Academy University Gothenburg SE431 80 Mölndal Sweden EMail annikaohrfelt neuroguse E X T R A Dement Geriatr Cogn Disord Extra 20166283294 284 DOI 101159000447239 2016 The Authors Published S Karger AG Basel wwwkargercomdee Öhrfelt et al Increased Cerebrospinal Fluid Levels Ubiquitin CarboxylTerminal Hydrolase L1 Patients Alzheimers Disease Background The ubiquitin proteasome UPS selectively degrades proteins targeted degra dation covalent conjugation ubiquitin 1 When proteins linked ubiquitin chain directed degradation UPS 1 lysosome 2 Alzheimers disease AD proteinmisfolding disease characterized accumulation amyloid β Aβ peptides hyperphosphorylated tau protein plaques neurofi brillary tangles respectively 3 The ubiquitin protein accumulated structural AD changes 47 This suggests dysfunction quality control mechanisms regu lating protein breakdown including UPS lysosome directly indi rectly involved pathogenesis AD Ubiquitin carboxylterminal hydrolase L1 UCHL1 called neuron cytoplasmic protein 95 PGP 95 highly abundant neuronspecific cytoplasmic enzyme 810 It modifies activity UPS acting deubiquitinating hydrolase 10 ubiquitin ligase 11 monoubiquitin stabilizer 12 UCHL1 13 ubiquitin 47 Aβ plaques neurofibrillary tangles AD brain supporting evidence UPS dysfunction AD Furthermore animal model dysfunction UCHL1 affected biological function tau protein phosphorylation tau 14 Genetic studies demonstrate link UCHL1 PARK5 gene rare familiar forms Parkinsons disease PD 15 previous studies shown protective effect S18Y poly morphism rs id 5030732 sporadic PD 16 17 There reports implications genetic variation UCHL1 AD 18 19 conflicting results terms role UCHL1 polymorphism AD patients 2022 UCHL1 levels cerebrospinal fluid CSF AD patients knowledge reported studies increased CSF ubiquitin level AD 2326 In CSF fluid surrounds central nervous AD core biomarkers totaltau Ttau tau phosphorylated threonine 181 Ptau 181 Aβ 142 thought reflect neurodegeneration neurofibrillary tangles aggregation Aβ plaques respec tively 27 Most studies confirm typical AD biomarker signature AD elevated Ttau Ptau addition reduced levels Aβ 142 Recently AD core CSF biomarkers included research criteria diagnosis early manifest AD International Working Group 28 diagnostic guidelines National Institute AgingAlzheimers Association 29 respectively However diagnostic performance CSF tau phosphorylated threonine 231 Ptau 231 compared CSF Ptau 181 known recent study Ptau 231 displayed greater overall specificity AD Ptau 181 30 The protein deglycase DJ1 PARK7 gene linked PD 31 Although role DJ1 fully evaluated provide protection oxidative stress 32 In previous studies CSF DJ1 levels unchanged AD 33 34 Neuronspecific enolase NSE glycolytic enzyme present neuronal neuroendocrine cells marker damage cortical nonmyelinated neurons 27 35 Several previous studies shown conflicting results reduced 36 increased 35 37 38 unchanged 39 40 CSF levels AD patients compared controls In study commercially available magnetic bead panel neurological disorders initially evaluated CSF samples subjects having AD core biomarker profile control core biomarker profile respectively The neurological panel assess CSF levels UCHL1 Ptau 231 DJ1 NSE wellcharacterized monocenter cohort patients cognitive impairment matched healthy controls 41 E X T R A Dement Geriatr Cogn Disord Extra 20166283294 285 Table 1 Demographic data biomarker levels pilot study patients AD controls based biomarker profile DOI 101159000447239 2016 The Authors Published S Karger AG Basel wwwkargercomdee Öhrfelt et al Increased Cerebrospinal Fluid Levels Ubiquitin CarboxylTerminal Hydrolase L1 Patients Alzheimers Disease Control biomarker profile AD biomarker profile Subjects menwomen n 31 1615 72 70 79 Age years Aβ1 42 ngl 779 636 991 276 170 332 Ttau ngl 43 28 49 Ptau181 ngl 45 38 5 3 UCHL1 μgl 406 314 495 Ptau231 pM 17 93 31 DJ1 μgl 23 16 29 NSE μgl 10 37 79 73 85 354 320 414b 1040 665 1110b 101 85 147b 12 76 14b 3810 2870 5070b 37 26 52a 42 38 56b Data given median interquartile range indicated Statistical differences determined nonparametric tests p 001 b p 00001 vs control Materials Methods CSF Samples Pilot Study An initial pilot study performed decoded human CSF samples supplied Clinical Neurochemistry Laboratory Sahlgrenska University Hospital Mölndal Patients designated control AD according CSF AD core biomarker levels inhouse opti mized cutoff levels 90 specific AD 42 Ttau 400 ngl Ptau 181 80 ngl Aβ 142 550 ngl The agematched test material included 10 patients AD biomarker profile 31 subjects control biomarker profile table 1 CSF Samples Clinical Study All CSF samples clinical study collected lumbar puncture L3L4 L4L5 interspace standardized time point 8 30 9 00 The 12 ml CSF collected polypropylene tube immediately transported local laboratory centrifugation 2000 g 4 C 10 min The supernatant pipetted gently mixed avoid possible gradient effects aliquoted polypropylene tubes stored 80 C pending biochemical analyses thawed refrozen The study participants AD CSF biomarker data clinical study reported previously 41 4346 The study consisted 60 patients 30 men 30 women Caucasian origin admitted general practitioner evaluation cognitive impairment memory clinic region Västra Götaland Sweden The patients examined single specialized physician PJ 20002008 Inclusion criteria referred evaluation suspected dementia age 6580 years body mass index BMI 2026 waisthip ratio 065090 women 070095 men Exclusion criteria serum creatinine 175 m M diabetes mellitus previous myocardial infarction malignancy including brain tumor subdural hematoma ongoing alcohol abuse medication cortisone previous present medication acetyl choline esterase inhibitors The study included agematched healthy controls 10 men 10 women recruited contemporaneously geographical area spouses included patients advertisements local newspapers The control subjects subjective symptoms cognitive dysfunction similar exclusion criteria patients E X T R A Dement Geriatr Cogn Disord Extra 20166283294 286 DOI 101159000447239 2016 The Authors Published S Karger AG Basel wwwkargercomdee Öhrfelt et al Increased Cerebrospinal Fluid Levels Ubiquitin CarboxylTerminal Hydrolase L1 Patients Alzheimers Disease All diagnoses assessed independent specialized physician previously described 41 The presence absence dementia diagnosed according Diag nostic Statistical Manual Mental Disorders Fourth Edition DSMIV criteria Patients dementia classified suffering AD 47 vascular dementia VaD according requirements NINDSAIREN 48 guidelines Erkinjuntti et al 49 subcortical type VaD Frontotemporal dementia PD dementia dementia Lewy bodies DLB diagnosed described previously 41 Mild cognitive impairment MCI diagnosed clinical setting patients cognitive impairment fulfill criteria dementia 50 Patients MCI followed annually median 3 range 17 years evaluate later developed dementia During followup visits 13 MCI patients remained stable cognitive function sMCI Others progressed dementia followup period diagnosed AD n 7 VaD n 3 frontotemporal lobe dementia n 1 MCI patients diagnosed AD followup visits differ CSF levels Aβ 142 Ttau Ptau patients established AD baseline In total study population consisted patients AD dementia MCI diagnosed AD dementia followup n 32 patients sMCI n 13 patients dementias n 15 healthy controls n 20 The distribution diagnoses dementia group VaD MCI diag nosed VaD followup n 10 DLB n 4 MCI later converted fronto temporal lobe dementia n 1 Before test day minimental state examination MMSE 51 performed CSF Analyses Measurements core AD biomarkers Aβ 142 Ttau Ptau 181 performed commercially available assays Fujirebio Ghent Belgium INNOTEST βAMYLOID142 INNOTEST hTAU Ag INNOTEST PHOSPHOTAU181P For clinical study core AD biomarkers analyzed occasion batch reagents previously reported 41 4346 Furthermore clinical study CSF hemoglobin concentrations measured human hemoglobin ELISA kit Bethyl Laboratories Inc according manufacturers protocol For clinical study red blood cells RBCs counted samples Hemoglobin levels 1000 ngl 52 andor 500 erythrocytes μl indicative significant blood contamination Only 80 CSF samples clinical study fulfilled criteria However samples excluded study statistical analyses showed results affected samples data shown MILLIPLEX MAP Human Neurological Disorders Magnetic Bead Panel 1 HND1MAG39K Merck Millipore quantification UCHL1 PARK5 DJ1 PARK7 NSE Ptau 231 NGFβ αsynuclein accordance protocol provided manufacturer 25 μl neat CSF analyzed DJ1 levels 48 μgl levels NSE 60 μgl set 48 60 μgl respectively Samples analyzed MAGPIX Merck Millipore Quality control QC samples QC1 QC2 analyzed duplicate supplied manufac turer fulfilled specified concentration levels Coefficients variation 8 analytes The levels NGFβ αsynuclein reported detection limit CSF samples pilot study clinical study Statistical Analysis Because distribution analytes skewed ShapiroWilk test p 005 nonparametric statistics statistical analysis SPSS version 200 statis tical software SPSS Inc Chicago Ill USA Data given stated median interquartile range Differences groups assessed E X T R A Dement Geriatr Cogn Disord Extra 20166283294 287 DOI 101159000447239 2016 The Authors Published S Karger AG Basel wwwkargercomdee Öhrfelt et al Increased Cerebrospinal Fluid Levels Ubiquitin CarboxylTerminal Hydrolase L1 Patients Alzheimers Disease Table 2 Demographic data biomarker levels clinical study Controls sMCI AD Other dementia Subjects menwomen n Age years MMSE Aβ1 42 ngl Ttau ngl Ptau181 ngl UCHL1 μgl Ptau231 pM DJ1 μgl NSE μgl 20 1010 75 70 78 29 27 29f 992 786 1038f 327 223 398f 65 50 79f 72 62 89f 1000 900 1200f 19 16 20 40 33 60 13 58 72 69 74 29 27 29f 671 544 833a f 270 230 390f 60 38 74f 74 51 89e 1200 700 1700f 14 12 16 33 31 60 32 1517 75 71 77 23 19 25c 420 336 493c 584 434 747c 98 78 113c 11 87 13c 3400 2700 3850c 17 13 19 50 34 60 15 105 74 72 77 24 20 26c 404 354 816a 311 260 380f 47 36 63a f 72 58 9f 1500 1100 1800f 71 63 18b d 30 26 34a d Data given median interquartile range indicated Statistical differences determined nonparametric tests The demographic data core AD biomarkers previously reported 41 43 46 p 005 b p 0001 c p 00001 vs control d p 005 e p 0001 f p 00001 vs AD KruskalWallis test If statistically significant p 005 MannWhitney U test pairwise comparisons The diagnostic value biomarker assessed receiver operating characteristic ROC curves values area curve AUC 95 confidence interval CI calculated GraphPad Prism 5 GraphPad Software Inc La Jolla Calif USA The correlation coefficients ρ calculated Spearman twotailed correlation test Significance obtained twotailed p value 005 Statement Ethics The study approved ethical committee University Gothenburg informed consent obtained participants The study conducted according Declaration Helsinki Results Pilot Study In pilot study CSF levels analytes UCHL1 DJ1 NSE Ptau 231 significantly higher group AD biomarker profile n 10 group control biomarker profile n 31 table 1 Clinical Samples Demographic Results CSF AD Biomarkers Table 2 shows demographic characteristics groups In clinical cohort patients controls comparable terms age gender BMI waisthip ratio Patients AD dementia significantly lower MMSE scores compared controls The core AD biomarkers clinical study previously reported 41 4345 The AD group showed significantly higher CSF levels Ttau Ptau 181 control group Aβ 142 concentration significantly decreased table 2 CSF levels Ptau 181 Aβ 142 significantly altered dementia group table 2 E X T R A Dement Geriatr Cogn Disord Extra 20166283294 288 DOI 101159000447239 2016 The Authors Published S Karger AG Basel wwwkargercomdee Öhrfelt et al Increased Cerebrospinal Fluid Levels Ubiquitin CarboxylTerminal Hydrolase L1 Patients Alzheimers Disease 20 15 10 5 0 40 30 20 10 0 l g μ 1 L H C U l g μ 1 J D c p 000003 p 0000001 8000 6000 4000 2000 M p 1 3 2 u t P Cont sMCI AD Other b p 0001 Cont sMCI AD Other 0 80 60 40 20 0 l g μ E S N d Cont sMCI AD Other p 002 Cont sMCI AD Other Fig 1 Individual values UCHL1 Ptau 231 b DJ1 c NSE d CSF samples healthy trols cont patients sMCI AD dementias The lower upper middle lines error bars correspond 25th 75th percentiles medians respectively CSF Concentrations UCHL1 PTau 231 DJ1 NSE The CSF levels UCHL1 Ptau 231 significantly increased patients AD compared controls biomarkers unaltered dementia sMCI fig 1 b table 2 The CSF levels DJ1 NSE unchanged AD group significantly decreased group dementia compared controls fig 1 c d table 2 ROC Curve Analysis UCHL1 Ptau 231 differentiate AD controls AUC 0854 95 CI 07460963 p 00001 0915 95 CI 08131018 p 00001 respectively fig 2 The AUC core AD biomarkers Aβ 142 Ttau Ptau 181 0938 95 CI 0865 1010 p 00001 0909 95 CI 08330986 p 00001 0844 95 CI 07360954 p 00001 respectively fig 2 DJ1 NSE differentiate dementia controls AUC 0835 95 CI 06790990 p 0001 0744 95 CI 0562 0927 p 002 respectively Correlation Analysis None investigated CSF biomarkers correlated age MMSE score hemo globin concentration control group patients AD table 3 The levels UCHL1 correlated positively levels Ptau 181 Ptau 231 DJ1 NSE E X T R A Dement Geriatr Cogn Disord Extra 20166283294 289 DOI 101159000447239 2016 The Authors Published S Karger AG Basel wwwkargercomdee Öhrfelt et al Increased Cerebrospinal Fluid Levels Ubiquitin CarboxylTerminal Hydrolase L1 Patients Alzheimers Disease Fig 2 ROC curve analysis UCHL1 black Ptau 231 purple Aβ 142 blue Ttau yellow Ptau 181 orange CSF samples differentiation AD patients n 32 controls n 20 clinical study AUC 0854 95 CI 07460963 p 00001 0915 95 CI 08131018 p 00001 0938 95 CI 0865 1010 p 00001 0909 95 CI 08330986 p 00001 0844 95 CI 07360954 p 00001 respectively Table 3 Correlation age MMSE hemoglobin biomarker levels clinical study 10 08 06 04 02 y t v t s n e S 0 0 02 04 06 08 10 1 specificity Controls n 20 Age MMSE Hemoglobin Aβ1 42 Ttau Ptau181 UCHL1 Ptau231 DJ1 AD n 32 Age MMSE Hemoglobin Aβ1 42 Ttau Ptau181 UCHL1 Ptau231 DJ1 UCHL1 Ptau231 DJ1 NSE ns ns ns ns ns 0698c ns ns ns ns 0588c 0526b ns ns ns ns 0792c 0835c 0588b ns ns ns ns 0894c 0921c 0491b ns ns ns ns ns 0580b 0506a ns ns ns ns 0383a 0673c 0636c 0658c 0597c ns ns ns ns ns ns 0617b ns ns ns ns ns ns 0652c 0618c 0522b 0512b 0400a Correlations presented Spearmans rank correlation coefficient ρ Nonsignificant ns p 005 correlations reported p 005 b p 001 c p 0001 control group AD patients table 3 Moreover UCHL1 levels correlated positively Ttau AD group control group table 3 The levels Ptau 231 corre lated positively CSF levels DJ1 NSE AD patients controls table 3 Finally CSF levels Ptau 231 correlated positively Ptau 181 Ttau control group patients AD table 3 E X T R A Dement Geriatr Cogn Disord Extra 20166283294 290 DOI 101159000447239 2016 The Authors Published S Karger AG Basel wwwkargercomdee Öhrfelt et al Increased Cerebrospinal Fluid Levels Ubiquitin CarboxylTerminal Hydrolase L1 Patients Alzheimers Disease Discussion In investigated CSF materials levels UCHL1 Ptau 231 significantly increased AD patients compared controls biomarkers unaltered dementias sMCI Moreover separation AD controls similar magnitude markers CSF core AD biomarkers Aβ 142 Ttau Ptau 181 In clinical study CSF levels DJ1 NSE unchanged AD group decreased group dementias compared controls To knowledge study assess potential UCHL1 CSF biomarker AD UCHL1 neuronalspecific enzyme highly abundant brain 810 enzymes involved regulation proteosomal degradation During process normal proteins short halflife misfolded proteins conjugated ubiquitin destines proteosomal 1 1012 andor lysosomal degradation 2 The UPS previously implicated pathogenesis AD UCHL1 present neurofibrillary tangles AD brain 13 53 Several previous studies reported increased CSF ubiquitin levels AD patients 2326 little previously known CSF UCHL1 level AD Our results CSF UCHL1 level increased AD CSF UCHL1 separate AD patients controls high diagnostic accuracy ROC curve analysis The CSF UCHL1 level correlate CSF levels Ttau Ptau positive correlation CSF levels UCHL1 NSE AD group controls Both Ttau NSE previously suggested general markers damage cortical nonmyelinated neurons 27 35 indicate finding elevated CSF UCHL1 level AD extent reflects neurodegeneration Recent reports suggest UCHL1 released brain damage caused acute neurological insults traumatic brain injury subarachnoid hemorrhage 54 55 Therefore diagnostic accuracy CSF UCHL1 separate AD brain damage causes needs investigated studies In contrast Ptau specific marker AD 27 high CSF levels Ptau correlate accumulation cortical neurofibrillary tangles 56 57 Thus positive correlation CSF UCHL1 CSF Ptau study combined previous findings neurofibrillary tangles AD ubiquitinated 47 numbers neurofibrillary tangles AD brains relate negatively level soluble UCHL1 18 support hypothesis elevated UCHL1 levels AD reflect higher expression UPS enzymes compensate higher load misfolded proteins Furthermore dysfunction UCHL1 animal model affected biological function tau phosphorylation tau 14 The elevated Ptau 231 level AD group concordance previous reports Ptau 231 Ptau 181 increased AD 5860 We confirm CSF levels Ptau 231 Ptau 181 correlate tightly 58 suggesting Ptau epitopes reflect pathogenic process interchangeably measure brain neurofibrillary tangle load 56 57 The results recent study suggested Ptau 231 greater overall specificity AD compared Ptau 181 30 However study similar perfor mance Ptau 231 Ptau 181 differentiating AD patients controls Ptau 181 performed better differentiating AD Lewy body dementia Ptau 231 performed better differentiating AD frontotemporal dementia 58 Further studies warranted settle difference diagnostic performance Ptau 231 Ptau 181 identify AD neurodegenerative disorders DJ1 PARK7 genetically linked PD 31 Even physiological function DJ1 fully evaluated thought play protective role oxidative stress E X T R A Dement Geriatr Cogn Disord Extra 20166283294 291 DOI 101159000447239 2016 The Authors Published S Karger AG Basel wwwkargercomdee Öhrfelt et al Increased Cerebrospinal Fluid Levels Ubiquitin CarboxylTerminal Hydrolase L1 Patients Alzheimers Disease 32 In accordance previous reports DJ1 level changed AD compared controls 33 34 NSE glycolytic enzyme present neuronal neuroen docrine cells associated neurodegeneration 27 35 Previous studies shown conflicting results reduced 36 increased 35 37 38 unchanged 39 40 CSF NSE levels AD compared controls In present study CSF levels NSE unaltered AD patients dementias CSF levels NSE DJ1 reduced However dementia group heterogeneous relatively cases specific diagnosis VaD DLB Therefore studies needed explore roles NSE DJ1 dementias AD The present study represents monocenter design clinical study strictly defined procedures lumbar puncture laboratory assays Patients controls matched terms age gender BMI waisthip ratio participants diabetes mellitus received treatment acetylcholine esterase inhibitors gluco corticoids One limitation clinical study crosssectional design changes time studied Furthermore lack separation AD patients controls terms CSF NSE levels explained NSE levels exceeding highest allowed level set highest standard concentration Moreover DJ1 NSE abundant RBCs CSF levels falsely elevated blood contami nation 33 61 We investigated RBC contamination assessment hemoglobin levels RBC counting samples confounded RBC contamination These samples excluded study additional statistical analyses showed samples affect final CSF result DJ1 NSE In addition DJ1 NSE correlated CSF hemoglobin Finally evaluated magnetic bead panel able measure NGFβ αsynuclein analyzed CSF samples The QC samples provided manufacturer fulfilled specified concentration levels suggesting multiassay sufficiently sensitive measure NGFβ αsynuclein CSF samples Conclusions In study evaluated magnetic bead panel neurological disorders CSF UCHL1 Ptau 231 levels elevated patients AD compared healthy controls The elevated CSF levels UCHL1 indirectly reflect disturbed proteosomal degradation released response general neurodegeneration AD In addition clinical study suggests UCHL1 additional CSF biomarker AD CSF Ptau 231 high diagnostic accuracy AD suggesting CSF Ptau 231 valid alternative CSF Ptau 181 CSF levels DJ1 NSE decreased dementia group group relatively small studies needed clarify role DJ1 NSE dementing disorders AD Acknowledgments The authors thank Carina Borén Department Neuropsychiatry Skaraborg Hospital Falköping Eva Bringman Dzemila Secic Department Psychiatry Neurochemistry Sahlgrenska University Hospital Mölndal excellent technical assis tance This work supported grants Swedish Research Council 52320077111 52120122288 20132546 European Research Council 681712 ALFLUA E X T R A Dement Geriatr Cogn Disord Extra 20166283294 292 DOI 101159000447239 2016 The Authors Published S Karger AG Basel wwwkargercomdee Öhrfelt et al Increased Cerebrospinal Fluid Levels Ubiquitin CarboxylTerminal Hydrolase L1 Patients Alzheimers Disease research grant Gothenburg ALFGBG438631 ALFGBG139671 ALFGBG441051 Lundberg Foundation Torsten Ragnar Söderberg Foundation Lundbeck Foun dation Sahlgrenska University Hospital Sahlgrenska Academy Stiftelsen Psykiatriska Forskningsfonden Stiftelsen Gamla Tjänarinnor Uppsala Universitets Medicinska Fakultet stiftelse för psykiatrisk och neurologisk forskning Alzheimer Foundation Sweden Torsten Söderberg Foundation Royal Swedish Academy Sciences Brain Foun dation Sweden Knut Alice Wallenberg Foundation Frimurarestiftelsen Dementia Association Sweden Disclosure Statement KB served consultant Eli Lilly Roche Diagnostics Advisory Boards Amgen IBL International KB HZ cofounders Brain Biomarker Solutions Gothenburg AB GU venturebased platform company University Gothenburg The authors disclose References 1 Thrower JS Hoffman L Rechsteiner M Pickart CM Recognition polyubiquitin proteolytic signal EMBO J 2000 19 94102 2 Haglund K Sigismund S Polo S Szymkiewicz I Di Fiore PP Dikic I Multiple monoubiquitination RTKs sufficient endocytosis degradation Nat Cell Biol 2003 5 461466 3 Blennow K Leon MJ Zetterberg H Alzheimers disease Lancet 2006 368 387403 4 Perry G Friedman R Shaw G Chau V Ubiquitin detected neurofibrillary tangles senile plaque neurites Alzheimer disease brains Proc Natl Acad Sci USA 1987 84 30333036 5 Mori H Kondo J Ihara Y Ubiquitin component paired helical filaments Alzheimers disease Science 1987 235 16411644 6 MorishimaKawashima M Hasegawa M Takio K Suzuki M Titani K Ihara Y Ubiquitin conjugated aminoterminally processed tau paired helical filaments Neuron 1993 10 11511160 7 Tabaton M Cammarata S Mancardi G Manetto V AutilioGambetti L Perry G et al Ultrastructural localization βamyloid tau ubiquitin epitopes extracellular neurofibrillary tangles Proc Natl Acad Sci USA 1991 88 20982102 8 Doran JF Jackson P Kynoch PA Thompson RJ Isolation PGP 95 new human neuronespecific protein detected highresolution twodimensional electrophoresis J Neurochem 1983 40 15421547 9 Wilson PO Barber PC Hamid QA Power BF Dhillon AP Rode J et al The immunolocalization protein gene product 95 rabbit polyclonal mouse monoclonal antibodies Br J Exp Pathol 1988 69 91104 10 Wilkinson KD Lee KM Deshpande S DuerksenHughes P Boss JM Pohl J The neuronspecific protein PGP 95 ubiquitin carboxylterminal hydrolase Science 1989 246 670673 11 Liu Y Fallon L Lashuel HA Liu Z Lansbury PT Jr The UCHL1 gene encodes opposing enzymatic activities affect αsynuclein degradation Parkinsons disease susceptibility Cell 2002 111 209218 12 Osaka H Wang YL Takada K Takizawa S Setsuie R Li H et al Ubiquitin carboxyterminal hydrolase L1 binds stabilizes monoubiquitin neuron Hum Mol Genet 2003 12 19451958 13 Lowe J McDermott H Landon M Mayer RJ Wilkinson KD Ubiquitin carboxylterminal hydrolase PGP 95 selectively present ubiquitinated inclusion bodies characteristic human neurodegenerative diseases J Pathol 1990 161 153160 14 Xie M Han Y Yu Q Wang X Wang S Liao X UCHL1 inhibition decreases microtubulebinding function tau protein J Alzheimers Dis 2015 49 353363 15 Leroy E Boyer R Auburger G Leube B Ulm G Mezey E et al The ubiquitin pathway Parkinsons disease Nature 1998 395 451452 16 Carmine Belin A Westerlund M Bergman O Nissbrandt H Lind C Sydow O et al S18Y ubiquitin carboxy terminal hydrolase L1 UCHL1 associated decreased risk Parkinsons disease Sweden Parkin sonism Relat Disord 2007 13 295298 17 Maraganore DM Lesnick TG Elbaz A ChartierHarlin MC Gasser T Krüger R et al UCHL1 Parkinsons disease susceptibility gene Ann Neurol 2004 55 512521 18 Choi J Levey AI Weintraub ST Rees HD Gearing M Chin LS et al Oxidative modifications downregu lation ubiquitin carboxylterminal hydrolase L1 associated idiopathic Parkinsons Alzheimers diseases J Biol Chem 2004 279 1325613264 E X T R A Dement Geriatr Cogn Disord Extra 20166283294 293 DOI 101159000447239 2016 The Authors Published S Karger AG Basel wwwkargercomdee Öhrfelt et al Increased Cerebrospinal Fluid Levels Ubiquitin CarboxylTerminal Hydrolase L1 Patients Alzheimers Disease 19 Sultana R BoydKimball D Cai J Pierce WM Klein JB Merchant M et al Proteomics analysis Alzheimers disease hippocampal proteome J Alzheimers Dis 2007 11 153164 20 Forero DA Benitez B Arboleda G Yunis JJ Pardo R Arboleda H Analysis functional polymorphisms synaptic plasticityrelated genes BDNF COMT UCHL1 Alzheimers disease Colombia Neurosci Res 2006 55 334341 21 Xue S Jia J Genetic association ubiquitin carboxyterminal hydrolaseL1 gene S18Y polymorphism sporadic Alzheimers disease Chinese Han population Brain Res 2006 1087 2832 22 Zetterberg M Sjolander A von Otter M Palmer MS Landgren S Minthon L et al Ubiquitin carboxyterminal hydrolase L1 UCHL1 S18Y polymorphism Alzheimers disease Mol Neurodegener 2010 5 11 23 Kandimalla RJ Anand R Veeramanikandan R Wani WY Prabhakar S Grover VK et al CSF ubiquitin specific biomarker Alzheimers disease Curr Alzheimer Res 2014 11 340348 24 Kandimalla RJ Prabhakar S Binukumar BK Wani WY Sharma DR Grover VK et al Cerebrospinal fluid profile amyloid beta42 Abeta42 hTau ubiquitin North Indian Alzheimers disease patients Neurosci Lett 2011 487 134138 25 Blennow K Davidsson P Wallin A Gottfries CG Svennerholm L Ubiquitin cerebrospinal fluid Alzheimers disease vascular dementia Int Psychogeriatr 1994 6 1322 discussion 5960 26 Oeckl P Steinacker P von Arnim CA Straub S Nagl M Feneberg E et al Intact protein analysis ubiquitin cerebrospinal fluid multiple reaction monitoring reveals differences Alzheimers disease frontotem poral lobar degeneration J Proteome Res 2014 13 45184525 27 Blennow K Hampel H Weiner M Zetterberg H Cerebrospinal fluid plasma biomarkers Alzheimer disease Nat Rev Neurol 2010 6 131144 28 Dubois B Feldman HH Jacova C Hampel H Molinuevo JL Blennow K et al Advancing research diagnostic criteria Alzheimers disease IWG2 criteria Lancet Neurol 2014 13 614629 29 McKhann GM Knopman DS Chertkow H Hyman BT Jack CR Jr Kawas CH et al The diagnosis dementia Alzheimers disease recommendations National Institute AgingAlzheimers Association workgroups diagnostic guidelines Alzheimers disease Alzheimers Dement 2011 7 263269 30 Spiegel J Pirraglia E Osorio RS Glodzik L Li Y Tsui W et al Greater specificity cerebrospinal fluid Ptau 231 Ptau 181 differentiation healthy controls Alzheimers Disease J Alzheimers Dis 2015 49 93100 31 Bonifati V Rizzu P van Baren MJ Schaap O Breedveld GJ Krieger E et al Mutations DJ1 gene associated autosomal recessive earlyonset parkinsonism Science 2003 299 256259 32 Taira T Saito Y Niki T IguchiAriga SM Takahashi K Ariga H DJ1 role antioxidative stress prevent cell death EMBO Rep 2004 5 213218 33 Hong Z Shi M Chung KA Quinn JF Peskind ER Galasko D et al DJ1 αsynuclein human cerebrospinal fluid biomarkers Parkinsons disease Brain 2010 133 713726 34 Gui YX Liu H Zhang LS Lv W Hu XY Altered microRNA profiles cerebrospinal fluid exosome Parkinson disease Alzheimer disease Oncotarget 2015 6 3704337053 35 Blennow K Wallin A Ekman R Neuron specific enolase cerebrospinal fluid biochemical marker neuronal degeneration dementia disorders J Neural Transm Park Dis Dement Sect 1994 8 183191 36 Cutler NR Kay AD Marangos PJ Burg C Cerebrospinal fluid neuronspecific enolase reduced Alzheimers disease Arch Neurol 1986 43 153154 37 Palumbo B Siepi D Sabalich I Tranfaglia C Parnetti L Cerebrospinal fluid neuronspecific enolase marker Alzheimers disease Funct Neurol 2008 23 9396 38 Schmidt FM Mergl R Stach B Jahn I Gertz HJ Schonknecht P Elevated levels cerebrospinal fluid neuron specific enolase NSE Alzheimers disease Neurosci Lett 2014 570 8185 39 Parnetti L Palumbo B Cardinali L Loreti F Chionne F Cecchetti R et al Cerebrospinal fluid neuronspecific enolase Alzheimers disease vascular dementia Neurosci Lett 1995 183 4345 40 Nooijen PT Schoonderwaldt HC Wevers RA Hommes OR Lamers KJ Neuronspecific enolase S100 protein 41 myelin basic protein lactate CSF dementia Dement Geriatr Cogn Disord 1997 8 169173 Johansson P Mattsson N Hansson O Wallin A Johansson JO Andreasson U et al Cerebrospinal fluid biomarkers Alzheimers disease diagnostic performance homogeneous monocenter population J Alzheimers Dis 2011 24 537546 44 43 42 Hansson O Zetterberg H Buchhave P Londos E Blennow K Minthon L Association CSF biomarkers incipient Alzheimers disease patients mild cognitive impairment followup study Lancet Neurol 2006 5 228234 Johansson P Almqvist EG Johansson JO Mattsson N Hansson O Wallin A et al Reduced cerebrospinal fluid level thyroxine patients Alzheimers disease Psychoneuroendocrinology 2013 38 10581066 Johansson P Almqvist EG Johansson JO Mattsson N Andreasson U Hansson O et al Cerebrospinal fluid CSF 25hydroxyvitamin D concentration CSF acetylcholinesterase activity reduced patients Alzheimers disease PLoS One 2013 8e81989 Johansson P Aberg D Johansson JO Mattsson N Hansson O Ahren B et al Serum cerebrospinal fluid levels insulinlike growth factorI IGFI IGFbinding protein3 IGFBP3 increased Alzheimers disease Psychoneuroendocrinology 2013 38 17291737 45 46 Aberg D Johansson P Isgaard J Wallin A Johansson JO Andreasson U et al Increased cerebrospinal fluid level insulinlike growth factorII male patients Alzheimers disease J Alzheimers Dis 2015 48 637646 E X T R A Dement Geriatr Cogn Disord Extra 20166283294 294 DOI 101159000447239 2016 The Authors Published S Karger AG Basel wwwkargercomdee Öhrfelt et al Increased Cerebrospinal Fluid Levels Ubiquitin CarboxylTerminal Hydrolase L1 Patients Alzheimers Disease 47 McKhann G Drachman D Folstein M Katzman R Price D Stadlan EM Clinical diagnosis Alzheimers disease report NINCDSADRDA Work Group auspices Department Health Human Services Task Force Alzheimers Disease Neurology 1984 34 939944 48 Roman GC Tatemichi TK Erkinjuntti T Cummings JL Masdeu JC Garcia JH et al Vascular dementia diag nostic criteria research studies Report NINDSAIREN International Workshop Neurology 1993 43 250260 49 Erkinjuntti T Inzitari D Pantoni L Wallin A Scheltens P Rockwood K et al Research criteria subcortical vascular dementia clinical trials J Neural Transm Suppl 2000 59 2330 50 Petersen RC Mild cognitive impairment diagnostic entity J Intern Med 2004 256 183194 51 Folstein MF Folstein SE McHugh PR Minimental state A practical method grading cognitive state patients clinician J Psychiatr Res 1975 12 189198 52 Hall S Ohrfelt A Constantinescu R Andreasson U Surova Y Bostrom F et al Accuracy panel 5 cerebro spinal fluid biomarkers differential diagnosis patients dementia andor parkinsonian disorders Arch Neurol 2012 69 14451452 53 Song S Jung YK Alzheimers disease meets ubiquitinproteasome Trends Mol Med 2004 10 565 570 54 DiazArrastia R Wang KK Papa L Sorani MD Yue JK Puccio AM et al Acute biomarkers traumatic brain injury relationship plasma levels ubiquitin Cterminal hydrolaseL1 glial fibrillary acidic protein J Neurotrauma 2014 31 1925 55 Lewis SB Wolper R Chi YY Miralia L Wang Y Yang C et al Identification preliminary characterization ubiquitin C terminal hydrolase 1 UCHL1 biomarker neuronal loss aneurysmal subarachnoid hemor rhage J Neurosci Res 2010 88 14751484 56 Tapiola T Alafuzoff I Herukka SK Parkkinen L Hartikainen P Soininen H et al Cerebrospinal fluid βamyloid 42 tau proteins biomarkers Alzheimertype pathologic changes brain Arch Neurol 2009 66 382389 57 Buerger K Ewers M Pirttila T Zinkowski R Alafuzoff I Teipel SJ et al CSF phosphorylated tau protein corre lates neocortical neurofibrillary pathology Alzheimers disease Brain 2006 129 30353041 58 Hampel H Buerger K Zinkowski R Teipel SJ Goernitz A Andreasen N et al Measurement phosphorylated tau epitopes differential diagnosis Alzheimer disease comparative cerebrospinal fluid study Arch Gen Psychiatry 2004 61 95102 59 Buerger K Zinkowski R Teipel SJ Tapiola T Arai H Blennow K et al Differential diagnosis Alzheimer disease cerebrospinal fluid levels tau protein phosphorylated threonine 231 Arch Neurol 2002 59 12671272 60 Kohnken R Buerger K Zinkowski R Miller C Kerkman D DeBernardis J et al Detection tau phosphorylated threonine 231 cerebrospinal fluid Alzheimers disease patients Neurosci Lett 2000 287 187190 61 Ramont L Thoannes H Volondat A Chastang F Millet MC Maquart FX Effects hemolysis storage condition neuronspecific enolase NSE cerebrospinal fluid serum implications clinical practice Clin Chem Lab Med 2005 43 12151217